US · Healthcare · Biotechnology
EPS came in at -0.32 against a street estimate of -0.36 — a beat of 11.1%.
Analysts rate Design Therapeutics Inc a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $21.00.
| Fund | Stake |
|---|---|
| SR ONE CAPITAL MANAGEMENT, LP | 10.43% |
| Logos Global Management LP | 4.79% |
| RA Capital Management, LLC | 4.75% |
| Point72 Asset Management, L.P. | 4.35% |
| Baker Bros Advisors LP | 4.13% |
| BlackRock Inc | 3.41% |
| Trails Edge Capital Partners, LP | 3.20% |
| Driehaus Capital Management LLC | 2.79% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 DESIGN THERAPEUTICS, INC. – 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash position: $12.9 million cash + $194.5 million investment securities = $20 | 2026-08-03 |
| Results announced · Q3 2026 DESIGN THERAPEUTICS, INC. - Q2 2026 SUMMARY HEADLINE NUMBERS • Cash Position: $207.4 million in cash, cash equivalents and investment securities as | 2026-08-03 |
| Shareholder vote results · Q2 2026 DESIGN THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares as of April 14, 2026: 62,441,429 shares of common stock • Stock ticker | 2026-06-11 |
| Company announcement · Q2 2026 DESIGN THERAPEUTICS, INC. (DSGN) – 8-K SUMMARY HEADLINE NUMBERS • DT-216P2 dose: 1 mpk (milligrams per kilogram) achieved mean improvement of 6.4 po | 2026-05-18 |
| Quarterly report · Q1 2026 DESIGN THERAPEUTICS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Investments: $222.8 million as of March 31, 2026 ($12.8M cash + $210.1M i | 2026-04-28 |
| Results announced · Q2 2026 DESIGN THERAPEUTICS, INC. - Q1 2026 SUMMARY HEADLINE NUMBERS • Net loss for Q1 2026: $17.6 million (vs. $17.7 million in Q1 2025) • Net loss per sha | 2026-04-28 |
| Proxy statement · Q2 2026 DESIGN THERAPEUTICS, INC. — 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect Simeon George, M.D., as Class II director for a t | 2026-04-23 |
| Annual report FY2025 DESIGN THERAPEUTICS, INC. — 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Public float (as of June 30, 2025): $114,342,718 • Shares outstandi | 2026-03-09 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Design Therapeutics Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.